Arca
Skip to content
Tools
Tools

Paroxysmal nocturnal hemoglobinuria

Drug research and approvals for paroxysmal nocturnal hemoglobinuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 29 studies of paroxysmal nocturnal hemoglobinuria are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, and FDA has 9 approved and 10 open orphan designations naming it.

  • Recruiting worldwide: 29
  • Trials authorized in Canada: 23
  • FDA orphan approvals: 9
  • EU medicines: 0

Recruiting now

Newest posted first, of 29 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 23; search them all in Canada trials
Jul 9, 2025A single arm study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria…Cemdisiran (ALN-CC5) / Pozelimab (REGN3918)RegeneronOngoing
Jun 30, 2025A phase 3 open-label study of danicopan as add-on treatment to ravulizumab or eculizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria who…Danicopan (ALXN2040)AstraZeneca PharmaceuticalsOngoing
May 7, 2025A randomized, double-blind, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of aln-cfb, an…Aln-cfb (ALN-1725763)RegeneronOngoing
Nov 21, 2022Long-term extension (LTE) study to characterize the safety and efficacy of danicopan as an add-on therapy to a complement component 5 inhibitor (C5I) in…Danicopan (ALXN2040)AstraZeneca PharmaceuticalsOngoing
Oct 6, 2022An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of pozelimab and cemdisiran combination therapy in patients with…Pozelimab (REGN3918) / Cemdisiran (ALN-CC5).RegeneronOngoing
Mar 16, 2022A randomized, open-label, ravulizumab-controlled study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with…Pozelimab (REGN3918) / Cemdisiran (ALN-CC5) / RavulizumabRegeneronOngoing
Sep 16, 2021A randomized, double-blind, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of oral BCX9930…BCX9930BioCryst PharmaceuticalsPending
Sep 8, 2021A randomized, open-label, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of oral BCX9930 monotherapy for the treatment of…BCX9930BioCryst PharmaceuticalsPending
Jul 28, 2021Phase 2 open-label proof of concept study to assess the efficacy, safety, andpharmacokinetics of the oral factor d (FD) inhibitor ALXN2050 (ACH-0145228)in…ALXN2050AstraZeneca PharmaceuticalsClosed
Nov 20, 2020A phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in adult and…Crovalimab (RO7112689) / EculizumabRocheClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 19
Jun 20, 2024PiaskyTreatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40…Genentech Inc.Approved
Mar 29, 2024VoydeyaAdd-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal…Alexion Pharmaceuticals, IncApproved
Dec 5, 2023FabhaltaTreatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)Novartis Pharmaceuticals CorporationApproved
Jul 22, 2022UltomirisTreatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH)Alexion Pharmaceuticals, Inc.Approved
Jun 7, 2021UltomirisTreatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH)Alexion Pharmaceuticals, Inc.Approved
May 14, 2021EmpaveliTreatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)Apellis Pharmaceuticals, Inc.Approved
Oct 9, 2020UltomirisULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).Alexion Pharmaceuticals, Inc.Approved
Dec 21, 2018UltomirisULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).Alexion Pharmaceuticals, Inc.Approved
Mar 16, 2007SolirisTreatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysisAlexion Pharmaceuticals, Inc.Approved
Dec 11, 2024Small molecule inhibitor of complement factor BTreatment of paroxysmal nocturnal hemoglobinuriaWuhan Createrna Science and Technology Co., Ltd.Designated
Dec 20, 2023Recombinant, Humanized, Aglycosylated, Immunoglobulin G1…Treatment of paroxysmal nocturnal hemoglobinuriaNovelMed Therapeutics, Inc.Designated
Oct 5, 2022Recombinant, Humanized, aglycosylated, IgG1 Kappa…Treatment of Paroxysmal Nocturnal HemoglobinuriaNovelMed Therapeutics, Inc.Designated
Jul 28, 2022Humanized immunoglobulin G4 monoclonal antibody directed…Treatment of Paroxysmal Nocturnal HemoglobinuriaNovo Nordisk Inc.Designated
Jul 20, 2022Recombinant IgG-fusion protein containing a humanized…Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)Kira Pharmaceuticals, LLCDesignated
Feb 10, 2022CemdisiranTreatment of paroxysmal nocturnal hemoglobinuriaRegeneron Pharamecuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.